Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu - AstraZeneca (NASDAQ:AZN), Daiichi Sankyo Co (OTC:DSNKY), Daiichi Sankyo Co (OTC:DSKYF)

Daiichi Sankyo Co Ltd DSKYF and AstraZeneca plc AZN have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (trastuzumab deruxtecan) for gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The trial will evaluate the safety and efficacy of Enhertu compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.
The primary endpoint of the trial is overall survival.
Secondary endpoints include investigator-assessed progression-free survival, objective response rate, duration of response, disease control rate, safety, pharmacokinetics, and immunogenicity.
The study will enroll approximately 490 patients.
Price Action: AZN shares are down 1.15% at $59.08 during the market session on the last check Thursday.

Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu